Cargando…
Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking
Co-stimulation signaling in various types of immune cells modulates immune responses in physiology and disease. Tumor necrosis factor receptor superfamily (TNFRSF) members such as CD40, OX40 and CD137/4-1BB are expressed on myeloid cells and/or lymphocytes, and they regulate antigen presentation and...
Autores principales: | Liu, Luyan, Wu, Yi, Ye, Kaiyan, Cai, Meichun, Zhuang, Guanglei, Wang, Jieyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295861/ https://www.ncbi.nlm.nih.gov/pubmed/35865955 http://dx.doi.org/10.3389/fphar.2022.924197 |
Ejemplares similares
-
Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
por: Stopforth, Richard J., et al.
Publicado: (2016) -
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
por: Teige, Ingrid, et al.
Publicado: (2019) -
FcγRIIb blockage: a promising immunotherapy target for severe COVID-19
por: He, Xuemei, et al.
Publicado: (2021) -
The Complex Association of FcγRIIb With Autoimmune Susceptibility
por: Verbeek, J. Sjef, et al.
Publicado: (2019) -
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy
por: Hussain, Khiyam, et al.
Publicado: (2022)